Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma

BACKGROUND: The advent of immune checkpoint inhibitors (ICIs) have led to a paradigm change in the management of metastatic renal cell carcinoma (mRCC), nevertheless, the benefit of treatment is confined to a limited proportion of patients. Therefore, the identification of predictive biomarkers for...

Descripción completa

Detalles Bibliográficos
Autores principales: Simonetti, Sonia, Iuliani, Michele, Stellato, Marco, Cavaliere, Silvia, Vincenzi, Bruno, Tonini, Giuseppe, Santini, Daniele, Pantano, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476128/
https://www.ncbi.nlm.nih.gov/pubmed/36104102
http://dx.doi.org/10.1136/jitc-2022-005136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476128/
https://www.ncbi.nlm.nih.gov/pubmed/36104102
http://dx.doi.org/10.1136/jitc-2022-005136

Ejemplares similares